ABSTRACT The efficacy of direct-acting antivirals (DAAs) in the treatment of chronic hepatitis C (CHC) in liver transplant recipients is poorly understood, and several factors, including immunosuppression, drug interactions, elevated viraemia, and intolerance to ribavirin (RBV), can reduce cure rates. We conducted a real-life study on liver transplant recipients with CHC treated with a combination of sofosbuvir (SOF) and daclatasvir (DCV) or simeprevir (SIM), with or without RBV, followed-up for 12 to 24 weeks. The treatment effectiveness was assessed by determining the sustained virological response (SVR) rates at 12 or 24 weeks after the treatment cessation. Eighty-four patients were evaluated, with a mean age of 63.4 ± 7.4 years, HCV genotype 1 being the most prevalent (63.1%). Nineteen patients (22.7%) had mild fibrosis (METAVIR < F2) and 41 (48.8%) significant fibrosis (METAVIR ≥ F2). The average time between liver transplantation and the start of treatment was 4 years (2.1-6.6 years). The SOF + DCV regimen was used in 58 patients (69%). RBV in combination with DAAs was used in seven patients (8.3%). SVR was achieved in 82 patients (97.6%), and few relevant adverse events could be attributed to DAA therapy, including a patient who stopped treatment due to a headache. There was a significant reduction in ALT, AST, GGT and FA levels, or the APRI index after 4 weeks of treatment, which remained until 12/24 weeks post-treatment. DAA treatment of CHC in liver-transplanted patients achieved a high SVR rate and resulted in the normalization of serum levels of liver enzymes.

ABSTRACT Schistosomiasis affects approximately 207 million people in 76 countries. The association between hepatocellular carcinoma and Schistosoma mansoni infection has been investigated. Studies using animal models suggest that the parasite may accelerate the oncogenic process when combined with other factors, such as hepatitis C virus infection or exposure to a carcinogen. Herein, we report a case series of six hepatocellular carcinoma patients from Northeast Brazil, with negative serology for both hepatitis B and C virus, submitted to liver transplantation, whose explant showed evidence of schistosomal liver fibrosis. Since all patients enrolled in this study were submitted to liver transplantation, we were able to access the whole explanted liver and perform histopathological analysis, which is often not possible in other situations. Although 50% of them showed signs of liver failure, no cirrhosis or any liver disease other than schistosomal fibrosis had been detected. These uncommon findings suggest that Schistosoma mansoni infection might predispose to hepatocellular carcinoma development, regardless of the absence of other risk factors.

OBJETIVO: Avaliar a acurácia da dosagem sérica de IGF-1 no diagnóstico da deficiência de hormônio de crescimento isolada (DGHI) ou combinada (DGHC) na fase de transição. SUJEITOS E MÉTODOS: Quarenta e nove pacientes com DGH na infância [16 DGHI (10 homens) e 33 DGHC (24 homens); idade 23,2 ± 3,5 anos] realizaram teste de tolerância à insulina (TTI), com pico de GH < 5 µg/L considerado diagnóstico de DGH na transição. Função hipofisária e níveis de IGF-1 foram determinados na amostra basal do TTI e os pacientes foram reclassificados em GH suficientes (SGH; n = 12), DGHI (n = 7) ou DGHC (n = 30). RESULTADOS: Cinco (31%) pacientes com DGHI e 32 (97%) com DGHC na infância persistiram com DGH no reteste. Um paciente com DGHI foi reclassificado como DGHC e três com DGHC como DGHI. Os picos médios de GH foram 0,2 ± 0,3 µg/L (DGHC), 1,3 ± 1,5 µg/L (DGHI) e 18,1 ± 13,1 µg/L (SGH). O nível médio de IGF-1 foi maior no grupo SGH (272 ± 107 ng/mL) comparado com DGHI (100,2 ± 110) e DGHC (48,7 ± 32,8) (p < 0,01). IGF-1 baixo foi observado em todos os pacientes reclassificados como DGHC, 86% dos DGHI e 8,3% dos SGH, resultando em sensibilidade de 97,3% e especificidade de 91,6% para detecção de DGH na transição; valor de corte de 110 ng/mL mostrou 94,5% sensibilidade e 100% especificidade. O nível médio de IGF-1 foi similar nos pacientes com DGHI ou DGHC com uma, duas, três ou quatro deficiências hipofisárias associadas. CONCLUSÃO: A dosagem sérica de IGF-1 mostrou-se acurada para substituir o TTI na detecção tanto de DGHI como DGHC na transição.

OBJECTIVE: To evaluate the accuracy of serum IGF-1 in the detection of isolated (IGHD) or combined growth hormone deficiency (CGHD) at the transition phase. SUBJECTS AND METHODS: Forty nine patients with GHD during childhood [16 with IGHD (10 men) and 33 with CGHD (24 men); age 23.2 ± 3.5 yrs.] were submitted to an insulin tolerance test (ITT) with a GH peak < 5 µg/L used for the diagnosis of GHD at the transition phase. Pituitary function and IGF-1 measurements were evaluated in the basal sample of the ITT. Transition patients were reclassified as GH-sufficient (SGH; n = 12), IGHD (n = 7), or CGHD (n = 30). RESULTS: Five (31%) patients with IGHD and 32 (97%) with CGHD at childhood persisted with GHD at retesting. One patient with IGHD was reclassified as CGHD, whereas 3 patients with CGHD were reclassified as IGHD. Mean GH peak was 0.2 ± 0.3 µg/L in the CGHD, 1.3 ± 1.5 µg/L in the IGHD, and 18.1 ± 13.1 µg/L in the SGH group. Serum IGF-1 level was significantly higher in the SGH (272 ± 107 ng/mL) compared to IGHD (100.2 ± 110) and CGHD (48.7 ± 32.8) (p < 0.01). All patients reclassified as CGHD, 86% reclassified as IGHD, and 8.3% reclassified as SGH had low IGF-1 level, resulting in 97.3% sensitivity and 91.6% specificity in the detection of GHD at the transition period; the cutoff value of 110 ng/mL showed 94.5% sensitivity and 100% specificity. Mean IGF-1 values did not differ in IGHD or CGHD associated with one, two, three, or four additional pituitary deficiencies. CONCLUSION: IGF-1 measurement is accurate to replace ITT as initial diagnostic test for IGHD and CGHD detection at the transition phase.

Em ambos os hospitais universitários de Pernambuco, o tratamento de escolha para portadores de esquistossomose hepatoesplênica (EHE) com antecedente de hemorragia digestiva alta (HDA) por rotura de varizes de esôfago (VE) é a esplenectomia associada à ligadura da veia gástrica esquerda (ELGE); porém, o impacto desta cirurgia sobre a pressão das VE, provavelmente, o parâmetro que melhor se correlaciona com o risco de recidiva hemorrágica, ainda não foi estudado. Com a introdução, em nosso meio, de técnica não-invasiva de medição da pressão das VE, isto tornou-se possível, com mínimos riscos, tomando-se o objetivo do presente estudo. A ELGE foi empregada em vinte portadores de EHE com antecedentes de HDA. A pressão das VE foi medida através do método endoscópico não-invasivo do balão pneumático, antes da cirurgia, e estes valores comparados com novas medições realizadas cinco a oito dias após. A pressão nas VE no pré-operatório variou entre 20,0 e 28,7mmHg (média de 24,35± 2,36 mmHg). Não houve correlação da pressão com o calibre das VE. No pós-operatório (PO), observou-se uma queda significante na pressão das VE, que variou entre 14,6 e 21,5 mmHg (média 17,29± 1,75 mmHg, p<0,001). Os resultados do presente trabalho confirmam as idéias que fundamentam a indicação da ELGE em portadores de EHE com antecedente de HDA. Esta cirurgia determina, pelo menos a curto prazo e na ampla maioria dos casos, uma redução na pressão das VE reduzindo o risco de recidiva de HDA.

Although splenectomy associated to left gastric vein ligature (SLGL) has been the standard procedure for the treatment of patients with hepatosplenic schistosomiasis (HSS) and previous upper digestive tract bleeding (UDB) originated from rupture of esophageal varices (EV) in both university hospitals in Pernanbuco, the effects of this procedure over the EV pressure, what is probably the parameter that offers the best correlation with bleeding recurrence, has not been studied yet. SLGL was performed in 20 patients with HSS and previous UDB. EV pressure was measured before surgery by the non-invasive endoscopic pneumatic balloon method. Pre-operative EV pressure values were compared with the new measurements performed 5 to 8 days after surgery. Pre-operative measurements of EV pressure ranged from 20.0 to 28.7 mmHg (average 243±52.36). No correlation between EV pressure and varices diameter was found. Post-operatively a significant decrease in EV pressure was observed (p<0.001), with measurements ranging from 14.6 to 21.5 (average 17.29±1.75). The results shown in this study ratify the idea of using SLGL in HSS patients with previous UDB as the standard procedure. SLGL induces, at least during a short period of time after surgery and in most of the cases, a reduction in EV pressure leading to a reduced risk of UDB recurrence.